P3 Health Partners (PIII) Cash & Equivalents (2019 - 2025)

P3 Health Partners (PIII) has reported Cash & Equivalents for 7 consecutive years, with $25.0 million the latest figure, recorded in Q4 2025.

• Cash & Equivalents for Q4 2025 came in at $25.0 million, down 35.57% year-over-year; the trailing twelve-month figure through Dec 2025 was $25.0 million (down 35.57% YoY), and the FY2025 annual result was $25.0 million, down 35.57% from the prior year.
• Cash & Equivalents was $25.0 million for Q4 2025 at P3 Health Partners, down from $37.7 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $110.3 million in Q1 2022 and troughed at $4.3 million in Q3 2021.
• Average Cash & Equivalents over 5 years is $38.7 million, with a median of $37.0 million recorded in 2023.
• Year-over-year, Cash & Equivalents jumped 692.27% in 2022 and sank 93.48% in 2023.
• Over 5 years, Cash & Equivalents stood at $5.3 million in 2021, then surged by 230.13% to $17.5 million in 2022, then surged by 107.54% to $36.3 million in 2023, then grew by 6.83% to $38.8 million in 2024, then sank by 35.57% to $25.0 million in 2025.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $25.0 million in Q4 2025, $37.7 million in Q3 2025, and $38.6 million in Q2 2025.